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Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-b (TGF-b) superfamily
and stimulate the osteoblast differentiation of various types of cells. Smads play central roles downstream
of BMP signaling. Receptor-regulated Smads (R-Smads) are phosphorylated by BMP receptors on 2 serine
residues in the Ser-X-Ser (SXS) motif at the C terminus. Phosphorylated R-Smads form heteromeric
complexes with Smad4 and directly activate the transcription of BMP-responsive genes such as Id1. In
contrast, the phosphorylation of a linker region of R-Smads by mitogen-activated protein kinases suppresses
their translocation to the nucleus and thus represses their transcriptional activity. Recently, distinct types of
phosphatases, i.e., small C-terminal domain phosphatases (SCPs) and protein phosphatase magnesium-
dependent 1A (PPM1A), have been identiﬁed as enzymes that suppress BMP activity by dephosphorylating
the C-terminal SXS motifs in Smads. In this review, we focus on these Smad phosphatases and the role of the
phosphorylation and dephosphorylation of Smad by introducing our own studies. To determine the role of
the phosphorylation and dephosphorylation of Smad1, we used a constitutively active Smad1 mutant
expression plasmid, Smad1 (DVD), in which the C-terminal serine residues have been substituted by aspartic
acids. PPM1A and SCP1 suppressed the activity of Smad1 (DVD). PPM1A suppressed the osteoblast
differentiation induced by BMPs by decreasing Smad protein levels. In contrast, SCP1 did not reduce Smad
protein levels but suppressed osteoblast differentiation to target the downstream effectors of Smad, especially
Runx2. In conclusion, SCP1 and PPM1A suppress the osteoblast differentiation induced by BMPs independent
of Smad dephosphorylation.
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Bone morphogenetic proteins (BMPs) are members of the trans-
forming growth factor-b (TGF-b) superfamily, which regulates the
differentiation, proliferation, and death of various types of cells [1].
BMPs were originally identiﬁed as factors that induce ectopic bone
formation when implanted into muscle tissues [2]. BMPs stimulate
the osteoblastic differentiation of various types of cells in vitro [3,4].
BMP signaling is transduced by 2 different types of transmem-
brane serine/threonine kinase receptors termed as type I and IIby Elsevier B.V. All rights reserved.
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Fig. 2. Smad1 is phosphorylated by several kinases. The activation of BMP type I
receptor kinase (BMPR-I) leads to the C-terminal phosphorylation of Smad1 (1).
Activated mitogen-activated protein kinase (MAPK) downstream of multiple inputs,
such as ﬁbroblast growth factor (FGF) or Ras, can phosphorylate the linker region (2) to
provide a primed substrate for GSK3b, which, in turn, is active in the absence of Wnt
signaling (3). Smad ubiquitination regulatory factor 1 (Smurf1) recognizes the doubly
phosphorylated linker region of Smad1 and polyubiquitinates (Ub) it (4), thus targeting
Smad1 for degradation by the proteasome (5). This ﬁgure is modiﬁed from Ref. [21].
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the type I receptor, and the activated type I receptor, in turn,
phosphorylates downstream substrates such as receptor-regulated
Smads (R-Smads), including Smad1, Smad5, and Smad8, in addition
to mitogen-activated protein kinases (MAPKs) such as Erk, Jnk, and
p38 [7].
Smads play central roles among the downstream signaling
effectors of BMP receptors. R-Smads are phosphorylated by BMP
receptors on 2 serine residues in the Ser-X-Ser (SXS) motif at the C
terminus [8–10]. Phosphorylated R-Smads form heteromeric
complexes with Smad4 and directly activate the transcription
of BMP-responsive genes, including Id1, Id2, and Id3, within an
hour (Fig. 1) [11–14]. Osterix (Osx) and Runx2 are both master
regulators of osteoblast differentiation and are indirectly acti-
vated by Smads within several hours [15,16].
In contrast, the phosphorylation of a linker region of R-Smads by
MAPKs suppresses their translocation to the nucleus and thus,
represses their transcriptional activity [17,18]. In addition, the phos-
phorylation of a Smad linker region by MAPKs or GSK3b plays an
important role in Smad degradation [19,20] and therefore, results in
the suppression of the activities of these proteins. The activated BMP
type I receptor phosphorylates the C-terminus of Smad1 (1). Acti-
vated MAPKs downstream of ﬁbroblast growth factor (FGF) or Ras,
phosphorylate MAPK phosphorylation sites in the linker region of
Smad1 (2) to provide a primed substrate for GSK3b, which is active in
the absence of Wnt signaling (3). Smad ubiquitination regulatory
factor 1 (Smurf1), which is a member of the E3 ubiquitin ligase
family, recognizes the doubly phosphorylated linker domain of
Smad1 and polyubiquitinates (Ub) it (4). Finally, Smad1 is degraded
in the proteasome (5) (Fig. 2) [21].
Although the phosphorylation of Smads is recognized to play a
critical role in BMP signal transduction, as described above, the
dephosphorylation of Smads has not been well studied, and its role
has remained elusive. However, distinct types of phosphatases, i.e.,
small C-terminal domain phosphatases (SCPs) and protein phospha-
tase magnesium-dependent 1A (PPM1A), have recently been identi-
ﬁed as enzymes that stimulate the dephosphorylation of SmadsNH
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Fig. 1. Bone morphogenetic proteins (BMPs) bind the BMP type I and type II receptor
receptor by phosphorylation. The activated type I receptor kinase phosphorylates 2 seri
Smad5, and Smad8 form heteromeric complexes with Smad4 and translocate to the nuc
authors.[22–24]. SCP1 and PPM1A suppress BMP activity by dephosphor-
ylating the C-terminal SXS motifs in Smad proteins [22,24]. In
addition, SCP1 dephosphorylates the MAPK phosphorylation sites in
the linker region of Smads (Fig. 3) [19]. Here, we discuss these Smad
phosphatases and the role of the phosphorylation and dephosphor-
ylation of Smad by introducing our own studies.2. SCP1 and PPM1A suppress Smad1
To determine the role of the phosphorylation and dephosphoryla-
tion of Smad1, we used a constitutively active Smad1 mutant
expression plasmid, Smad1 (DVD), in which the C-terminal serineCOOH Ser Val Ser 
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Fig. 3. SCP1 and PPM1A dephosphorylate phospho-Smad1. The Smad1 C-terminal or MAPK phosphorylation sites in the linker region are phosphorylated by BMPR-I and
MAPKs, respectively. Whereas small C-terminal domain phosphatase 1 (SCP1) dephosphorylates both the C-terminal and MAPK phosphorylation sites of Smad1, protein
phosphatase magnesium-dependent 1A (PPM1A) dephosphorylates only the C-terminus. This ﬁgure is modiﬁed from Ref. [19].
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Fig. 4. SCP1 and PPM1A suppress constitutively active Smad1 (DVD). The constitutively active form Smad1, termed Smad1 (DVD), in which the carboxy-terminal serine
residues of wild-type Smad1 have been substituted by aspartic acids (A). C2C12 cells were co-transfected with SCP1, PPM1A, or an empty vector, along with Smad1 (DVD,
B). C2C12 cells were co-transfected with wild-type SCP1, phosphatase activity-deﬁcient mutant of SCP1, wild-type PPM1A, phosphatase activity-deﬁcient mutant of
PPM1A, or an empty vector, along with Smad1 (DVD-MAPK), in which the MAPK phosphorylation sites in the linker region of Smad1 (DVD) were replaced with alanine
residues. The enzyme activity of alkaline phosphatase (ALP) was determined on day 3. Data are presented as the means7S.D. (n¼3). **Po0.01 in comparison with cells
transfected with an empty vector in each group. This ﬁgure is modiﬁed from Ref. [26].
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mutant, Smad1 (DVD), is able to induce alkaline phosphatase (ALP)
activity, which is a typical maker of osteoblast differentiation without
the use of BMP ligands or BMP receptors [25].
We ﬁrst examined the effect of SCP1 and PPM1A on Smad1
(DVD) and found that SCP1 and PPM1A robustly suppressed the
ALP activity induced by Smad1 (DVD), even though Smad1 (DVD)
lacks the serine residues at the C terminus that are known to be
dephosphorylated by SCP1 and PPM1A (Fig. 4B). We also gener-
ated another Smad1, MAPK-DVD, in which the 4 MAPK phosphor-
ylation sites in the linker region of Smad1 (DVD) were replaced
with alanine residues because SCP1 dephosphorylates MAPK
phosphorylation sites in addition to the C-terminal sites of Smad
[19]. Again, the ALP activity induced by Smad1 (MAPK-DVD) was
reduced by SCP1 and PPM1A (Fig. 4C) [26].
To determine whether phosphatase activity is required for the
action of SCP1 and PPM1A on Smad1 (MAPK-DVD), we generated a
phosphatase activity-deﬁcient mutants SCP1 and PPM1A [19,27]. In
contrast to the wild type, neither of the mutants suppressed the ALPactivity induced by Smad1 (MAPK-DVD) (Fig. 4C). These data
suggest that the inhibitory effect of SCP1 and PPM1A on BMP-
induced osteoblast differentiation is dependent on their phospha-
tase activities but independent of the dephosphorylation of the
Smads at their C-termini and MAPK phosphorylation sites in the
linker region [26].3. SCP1 and PPM1A target different stages of osteoblast
differentiation
Id genes have been identiﬁed as early BMP-responsive genes in
human and murine cells [13]. The mRNA expression of marker
genes that are characteristic of osteoblastic differentiation such as
Osx, ALP, and Osteocalcin (OC) was suppressed by both SCP1 and
PPM1A. In contrast, the expression of Id1, Id2, Id3, and Runx2
mRNA was suppressed by PPM1A but not SCP1 (Fig. 5A). These
data suggest that SCP1 and PPM1A target different stages of BMP
signaling-induced osteoblast differentiation [26].
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Fig. 5. SCP1 and PPM1A target different stages of osteoblast differentiation. The effect of SCP1 and PPM1A on the mRNA expression induced by Smad1 (DVD). C2C12 cells
were co-transfected with SCP1, PPM1A or an empty vector, along with Smad1 (DVD). The expression levels of the indicated mRNAs were determined by reverse
transcriptase-polymerase chain reaction (RT-PCR) performed on day 2 (A). C2C12 cells were co-transfected with SCP1, PPM1A, or an empty vector, along with Runx2. The
expression levels of OC mRNAs were determined by real-time PCR (B). C2C12 cells were co-transfected with SCP1, dominant negative Runx2 (DN), or an empty vector,
along with the 6xOSE2-luc reporter (C). The data are presented as the means7S.D. (n¼3). **Po0.01 in comparison with cells transfected with an empty vector in each
group. This ﬁgure is modiﬁed from Ref. [26].
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Fig. 6. PPM1A decreases the protein levels of Smad1 via the proteasome pathway. C2C12 cells were co-transfected with Myc-Smad1 (DVD) (A), Myc-Smad1 (WT) (B), or
Smad1 (AAAY) (C), in which the PPAY motif in the linker region was destroyed, and FLAG-PPM1A or an empty vector. C2C12 cells were treated with 10 mM lactacystin or
vehicle (dimethyl sulfoxide [DMSO]) for 8 h (B). Immunohistochemical analysis was performed on day 2 after transfection. This ﬁgure is modiﬁed from Ref. [34].
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entiation and acts downstream of BMP signaling [15,28]. Over-
expression of Runx2 increased the mRNA expression of genes that
are related to osteoblastic differentiation such as Osx, ALP, and
OC. The increased mRNA levels of Osx, ALP, and OC induced by
Runx2 were suppressed by SCP1 but were only weakly sup-
pressed by PPM1A (Fig. 5B). SCP1 did not suppress the transcrip-
tional activity of Runx2, as evaluated by the 6xOSE-2-luc reporter,
which contains the mouse osteocalcin promoter OSE2 response
element [29] and did not change the phospho-serine and phos-
pho-threonine levels of Runx2 (Fig. 5C) [26]. These data indicate
that SCP1 targets elements that are downstream of Runx2 in
BMP-induced osteoblastic differentiation.4. PPM1A decreases the protein levels of Smad1 via the
proteasome pathway
Finally, we examined the effect of PPM1A on the Smad1 (DVD)
protein levels. Western blot analysis showed that the protein
levels of Smad1 (DVD) were reduced when it was co-expressed
with PPM1A (Fig. 6A). Because the proteasome pathway plays a
key role in Smad degradation [30,31], we examined whether thispathway is also involved in the action of PPM1A. Treatment with
lactacystin, which is a speciﬁc inhibitor of the proteasome, pre-
vented the decrease in the Smad1 protein levels by PPM1A
(Fig. 6B). Smurf1 is a Smad ubiquitin ligase that stimulates Smad
degradation via the proteasome pathway by interacting with a
conserved PPAY motif in the linker regions of Smads [19,32,33].
Because the substitution of the PPAY motif with AAAY destroys
the above-mentioned interaction, we introduced this mutation
into wild-type Smad1, which we named Smad1 (AAAY). The co-
expression of PPM1A with Smad1 (AAAY) reduced the protein
levels of Smad1 (AAAY) (Fig. 6C). Taken together, these data
suggest that PPM1A decreases the Smad1 protein levels via the
proteasome pathway but that the interaction between Smurf1 and
Smad1 via the PPAY motif is not involved in this degradation [34].5. Conclusions
In this review, we presented the novel mechanisms by which
2 distinct types of Smad phosphatases strongly suppress BMP-
induced osteoblast differentiation independent of Smad depho-
sphorylation. Speciﬁcally, in addition to the dephosphorylation
of Smads, SCP1 suppresses osteoblast differentiation to target the
BMPs
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Fig. 7. Model of how SCP1 and PPM1A suppress the osteoblast differentiation induced by BMPs. In addition to the dephosphorylation of Smads, SCP1 suppresses the BMP-
induced osteoblast differentiation to target the downstream effectors of Smads, and PPM1A suppresses BMP signaling by decreasing the protein levels of Smads via the
proteasome pathway. This ﬁgure was prepared by the authors.
S. Kokabu et al. / Journal of Oral Biosciences 54 (2012) 73–78 77downstream effectors of Smad, especially Runx2, and PPM1A
suppresses BMP signaling by decreasing the protein levels of
Smads via the proteasome pathway (Fig. 7).
For some time, BMPs have been thought to be useful for
mandible bone regeneration because of their strong bone-induc-
tive effect. However, the clinical application of BMPs has not been
widespread, even though a quarter of a century has passed since
their cDNA was ﬁrst cloned. One of the reasons for this lack of
clinical efﬁcacy is that primates such as humans demonstrate
poor responses to BMPs and require high doses of BMPs to obtain
the same osteoinductive effects observed in rodents [35].
SCP1 and PPM1A are abundant in bone and physiologically
suppress BMP-induced osteoblast differentiation because small
interfering RNAs for SCP1 and PPM1A increased the osteoblast
differentiation induced by BMPs [26,34]; these phosphatases may
thus represent novel targets in new bone reconstruction methods.
Reducing the mRNA expression and/or enzyme activity of these
phosphatases could be useful for increasing the endogenous BMP
signaling and responsiveness to the topical application of BMPs.
Cyclin-dependent kinases 8 and 9 were recently reported to
phosphorylate the Smad1 linker region and increase its activity
[36]. Thus, the roles of the phosphorylation and dephosphoryla-
tion of the Smads are currently one of the important topics in
BMP signaling but remain to be fully elucidated.
In conclusion, SCP1 and PPM1A suppress the osteoblast differ-
entiation induced by BMPs independent of Smad dephosphorylation.Conﬂict of interest
No potential conﬂicts of interest are disclosed.Acknowledgments
S. Kokabu thanks the members of the Division of Pathophy-
siology, Research center for Genomic Medicine, Saitama Medical
University, of the Department of Oral and Maxillofacial, Faculty ofMedicine, Saitama Medical University, and of the Harvard School
of Dental Medicine for their valuable comments and discussion.
S. Kokabu also thanks Dr. Tamura, Dr. Kuroda, Dr. Kurihashi, and
Dr. Yuasa for support during his PhD course. S. Kokabu appreci-
ates two YK who supported and encouraged him at all times.
S. Kokabu was a recipient of a fellowship of Saitama Medical
University (2009–2010), and S. Kokabu is supported by a Dean’s
scholar award at the Harvard School of Dental Medicine (2011–
2012).References
[1] Rosen V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 2006;1068:
19–25.
[2] Urist MR. Bone: formation by autoinduction. Science 1965;150:893–9.
[3] Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V. Recombi-
nant human bone morphogenetic protein-2 induces osteoblastic differentia-
tion in W-20-17 stromal cells. Endocrinology 1992;130:1318–24.
[4] Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V,
Wozney JM, Fujisawa-Sehara A, Suda T. Bone morphogenetic protein-2
converts the differentiation pathway of C2C12 myoblasts into the osteoblast
lineage. J Cell Biol 1994;127:1755–66.
[5] Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res
Commun 2005;328:651–7.
[6] Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional
targets, regulation of signals, and signaling cross-talk. Cytokine Growth
Factor Rev 2005;16:251–63.
[7] Katagiri T, Suda T, Miyazono K. The bone morphogenetic proteins. In:
Derynck R, Miyazono K, editors. TGF-b family. New York: Cold Spring Harbor
Press; 2008. p. 121–49.
[8] Hoodless PA, Haerry T, Abdollah S, Stapleton M, O’Connor MB, Attisano L,
Wrana JL. MADR1, a MAD-related protein that functions in BMP2 signaling
pathways. Cell 1996;85:489–500.
[9] Chen Y, Bhushan A, Vale W. Smad8 mediates the signaling of the ALK-2
receptor serine kinase. Proc Natl Acad Sci USA 1997;94:12938–43.
[10] Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T. Smad5 and
DPC4 are key molecules in mediating BMP-2-induced osteoblastic differen-
tiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem
1998;273:1872–9.
[11] Lopez-Rovira T, Chalaux E, Massague J, Rosa JL, Ventura F. Direct binding of
Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic
protein-speciﬁc transcriptional activation of Id1 gene. J Biol Chem 2002;277:
3176–85.
S. Kokabu et al. / Journal of Oral Biosciences 54 (2012) 73–7878[12] Liu CJ, Ding B, Wang H, Lengyel P. The MyoD-inducible p204 protein
overcomes the inhibition of myoblast differentiation by Id proteins. Mol Cell
Biol 2002;22:2893–905.
[13] Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R. Identiﬁcation of
a BMP-responsive element in Id1, the gene for inhibition of myogenesis.
Genes Cells 2002;7:949–60.
[14] Hollnagel A, Oehlmann V, Heymer J, Ruther U, Nordheim A. Id genes are
direct targets of bone morphogenetic protein induction in embryonic stem
cells. J Biol Chem 1999;274:19838–45.
[15] Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcrip-
tional activator of osteoblast differentiation. Cell 1997;89:747–54.
[16] Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de
Crombrugghe B. The novel zinc ﬁnger-containing transcription factor osterix
is required for osteoblast differentiation and bone formation. Cell 2002;108:
17–29.
[17] Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signaling
pathways converge on the TGF-beta family mediator Smad1. Nature 1997;389:
618–22.
[18] Aubin J, Davy A, Soriano P. In vivo convergence of BMP and MAPK signaling
pathways: impact of differential Smad1 phosphorylation on development
and homeostasis. Genes Dev 2004;18:1482–94.
[19] Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J. Balancing BMP
signaling through integrated inputs into the Smad1 linker. Mol Cell 2007
441–54.
[20] Fuentealba LC, Eivers E, Ikeda A, Hurtado C, Kuroda H, Pera EM, De Robertis
EM. Integrating patterning signals: Wnt/GSK3 regulates the duration of the
BMP/Smad1 signal. Cell 2007;131:980–93.
[21] Verheyen EM. Opposing effects of Wnt and MAPK on BMP/Smad signal
duration. Dev Cell 2007;13:755–6.
[22] Knockaert M, Sapkota G, Alarcon C, Massague J, Brivanlou AH. Unique players
in the BMP pathway: small C-terminal domain phosphatases dephosphor-
ylate Smad1 to attenuate BMP signaling. Proc Natl Acad Sci USA 2006;103:
11940–5.
[23] Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J,
Brunicardi FC, Shi Y, Chen YG, Meng A, Feng XH. PPM1A functions as a Smad
phosphatase to terminate TGF beta signaling. Cell 2006;125:915–28.
[24] Duan X, Liang YY, Feng XH, Lin X. Protein serine/threonine phosphatase
PPM1A dephosphorylates Smad1 in the bone morphogenetic protein signal-
ing pathway. J Biol Chem 2006;281:36526–32.
[25] Nojima J, Kanomata K, Takada Y, Fukuda T, Kokabu S, Ohte S, Takada T, Tsukui
T, Yamamoto TS, Sasanuma H, Yoneyama K, Ueno N, Okazaki Y, Kamijo R,Yoda T, Katagiri T. Dual roles of Smad proteins in the conversion from
myoblasts to osteoblastic cells by bone morphogenetic proteins. J Biol Chem
2010;285:15577–86.
[26] Kokabu S, Ohte S, Sasanuma H, Shin M, Yoneyama K, Murata E, Kanomata K,
Nojima J, Ono Y, Yoda T, Fukuda T, Katagiri T. Suppression of BMP-Smad
signaling axis-induced osteoblastic differentiation by small C-terminal domain
phosphatase 1, a Smad phosphatase. Mol Endocrinol 2011;25:474–81.
[27] JacksonMD, Fjeld CC, Denu JM. Probing the function of conserved residues in the
serine/threonine phosphatase PP2Calpha. Biochemistry 2003;42:8513–21.
[28] Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY,
Ryoo HM, Bae SC. Runx2 is a common target of transforming growth factor
beta1 and bone morphogenetic protein 2, and cooperation between
Runx2 and Smad5 induces osteoblast-speciﬁc gene expression in the plur-
ipotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000;20:
8783–92.
[29] Ducy P, Karsenty. G. Two distinct osteoblast-speciﬁc sis-acting elements
control expression of a mouse osteocalcin gene. Mol Cell Biol 1995;15:
1858–69.
[30] Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem
1998;67:425–79.
[31] Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins
structurally and functionally related to the E6-AP ubiquitin-protein ligase.
Proc Natl Acad Sci USA 1995;92:5249.
[32] Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH, SMAD A. ubiquitin ligase
targets the BMP pathway and affects embryonic pattern formation. Nature
1999;400:687–93.
[33] Ying SX, Hussain ZJ, Zhang YE. Smurf1 facilitates myogenic differentiation
and antagonizes the bone morphogenetic protein-2-induced osteoblast
conversion by targeting Smad5 for degradation. J Biol Chem 2003;278:
39029–36.
[34] Kokabu S, Nojima J, Kanomata K, Ohte S, Yoda T, Fukuda T, Katagiri T. Protein
phosphatase magnesium-dependent 1A-mediated inhibition of BMP signal-
ing is independent of Smad dephosphorylation. J Bone Miner Res 2010;25:
653–60.
[35] Seto I, Asahina I, Oda M, Enomoto S. Reconstruction of the primate mandible
with a combination graft of recombinant human bone morphogenetic
protein-2 and bone marrow. J Oral Maxillofac Surg 2001;59:53–61.
[36] Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S, Barlas A, Miller AN,
Manova-Todorova K, Macias MJ, Sapkota G, Pan D, Massague J. Nuclear CDKs
drive Smad transcriptional activation and turnover in BMP and TGF-beta
pathways. Cell 2009;139:757–69.
